Berk M, et al. - Researchers explored whether adjunctive aspirin or rosuvastatin, correlated with placebo, reduced depressive symptoms in young people (15–25 years). They enrolled individuals (aged 15–25 years) with moderate to severe major depressive disorder (MADRS mean at baseline 32.5 ± 6.0; N = 130; age 20.2 ± 2.6; 60% female), between June 2013 and June 2017 across six sites in Victoria, Australia. In young people, they noted that the addition of either aspirin or rosuvastatin did not confer any beneficial impact over and above routine treatment for depression. At week 12, they recorded that statins were superior to aspirin on the MADRS, the Clinical Global Impressions Severity Scale (CGI-S), and the Negative Problem Orientation Questionnaire scale (NPOQ). In youth depression, exploratory comparisons of secondary outcomes give limited support for a potential therapeutic role for adjunctive rosuvastatin, but not for aspirin.